The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | The clinical efficacy of bexmarilimab and azacitidine in HR-MDS: current data and future outlooks
Mika Kontro, MD, PhD, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland, shares insights into the clinical efficacy of bexmarilimab in combination with azacitidine for patients with higher-risk myelodysplastic syndromes (HR-MDS). He discusses the mechanism of action of bexmarilimab and highlights results from the BEXMAB trial (NCT05428969). This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
